Potential for Improved Glycemic Control with Dietary Momordica charantia in Patients with Insulin Resistance and Pre-Diabetes

被引：43

作者：

Efird, Jimmy T. ^{[1
,2
]}

Choi, Yuk Ming ^{[3
]}

Davies, Stephen W. ^{[4
]}

Mehra, Sanjay ^{[5
]}

Anderson, Ethan J. ^{[6
,7
]}

Katunga, Lalage A. ^{[6
]}

机构：

[1] E Carolina Univ, East Carolina Heart Inst, Greenville, NC 27834 USA

[2] E Carolina Univ, Ctr Hlth Dispar, Brody Sch Med, Greenville, NC 27834 USA

[3] Univ N Carolina, Sch Nursing, Adult Gerontol Nurse Practitioner Program, Greensboro, NC 27402 USA

[4] Univ Virginia, Sch Med, Dept Gen Surg, Charlottesville, VA 22908 USA

[5] E Carolina Univ, Brody Sch Med, Dept Cardiovasc Sci, Greenville, NC 27834 USA

[6] E Carolina Univ, Dept Pharmacol & Toxicol, Brody Sch Med, Greenville, NC 27834 USA

[7] E Carolina Univ, East Carolina Diabet & Obes Inst ECDOI, East Carolina Heart Inst, Greenville, NC 27834 USA

来源：

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH | 2014年 / 11卷 / 02期

关键词：

Momordica charantia; bitter melon; insulin resistance; pre-diabetes; glycemic control; TYPE-2; DIABETES-MELLITUS; BITTER-MELON; HYPOGLYCEMIC ACTIVITY; AMERICAN ASSOCIATION; GLUCOSE-TOLERANCE; CLINICAL-TRIALS; PLANT SOURCE; BETA-CELLS; EXTRACT; RATS;

D O I：

10.3390/ijerph110202328

中图分类号：

X [环境科学、安全科学];

学科分类号：

08 ; 0830 ;

摘要：

Bitter Melon (Momordica charantia) is a widely used traditional remedy for hyperglycemia. While the medicinal properties of this plant have been studied extensively using in vitro and animal models, the clinical efficacy and safety in humans is largely unknown. This review discusses the benefits and limitations of bitter melon supplementation in the context of epidemic levels of insulin resistance and pre-diabetes throughout the world.

引用

页码：2328 / 2345

页数：18

共 66 条

[41] AN INVITRO STUDY ON THE EFFECT OF MOMORDICA-CHARANTIA ON GLUCOSE-UPTAKE AND GLUCOSE-METABOLISM IN RATS [J].

MEIR, P ;

YANIV, Z .

PLANTA MEDICA, 1985, 51 (01) :12-16

[42] Mechanisms of Vascular Complications in Prediabetes [J].

Milman, Sofiya ;

Crandall, Jill P. .

MEDICAL CLINICS OF NORTH AMERICA, 2011, 95 (02) :309-+

[43] A review of the epidemiology of diabetes in rural India [J].

Misra, P. ;

Upadhyay, R. P. ;

Misra, A. ;

Anand, K. .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 92 (03) :303-311

[44] Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions [J].

Nerurkar, Pratibha V. ;

Lee, Yun Kyung ;

Motosue, Megan ;

Adeli, Khosrow ;

Nerurkar, Vivek R. .

BRITISH JOURNAL OF NUTRITION, 2008, 100 (04) :751-759

[45] Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells [J].

Nerurkar, PV ;

Pearson, L ;

Efird, JT ;

Adeli, K ;

Theriault, AG ;

Nerurkar, VR .

JOURNAL OF NUTRITION, 2005, 135 (04) :702-706

[46] Momordica charantia for type 2 diabetes mellitus [J].

Ooi, Cheow Peng ;

Yassin, Zaitun ;

Hamid, Tengku-Aizan .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (02)

[47]

Phillippine Council for Health Research and Development, DOH REINST AMP DIAB

[48]

PONS JA, 1943, PUERTO RICO J PUBLIC, V19, P196

[49] Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae) [J].

Raman, A ;

Lau, C .

PHYTOMEDICINE, 1996, 2 (04) :349-362

[50] Traditional Indian Medicines Used for the Management of Diabetes Mellitus [J].

Rizvi, Syed Ibrahim ;

Mishra, Neetu .

JOURNAL OF DIABETES RESEARCH, 2013, 2013

← 1 2 3 4 5 6 7 →